Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.

Goswami, Hardik; Alsumali, Adnan; Jiang, Yiling; Schindler, Matthias; Duke, Elizabeth R; Cohen, Joshua; Briggs, Andrew; Puenpatom, Amy

Goswami, Hardik; Alsumali, Adnan; Jiang, Yiling; Schindler, Matthias; Duke, Elizabeth R; Cohen, Joshua; Briggs, Andrew; Puenpatom, Amy.

Afiliación

Goswami H; BARDS-Health Economics and Decision Science, Merck & Co, Inc., Kenilworth, NJ, USA. hardik.goswami@merck.com.
Alsumali A; BARDS-Health Economics and Decision Science, Merck & Co, Inc., 770 Sumneytown Pike, West Point, PA, 19486, USA. hardik.goswami@merck.com.
Jiang Y; BARDS-Health Economics and Decision Science, Merck & Co, Inc., Kenilworth, NJ, USA.
Schindler M; BARDS-Health Economics and Decision Science MSD (UK) Ltd, London, UK.
Duke ER; BARDS-HTA, MSD Ltd, Zurich, Switzerland.
Cohen J; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Briggs A; Center for the Evaluation of Value and Risk in Health, Boston, MA, USA.
Puenpatom A; London School of Hygiene and Tropical Medicine, London, UK.

Pharmacoeconomics ; 41(5): 605, 2023 May.

Article en En | MEDLINE | ID: mdl-36928836

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google